Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.
Granules India has reported consolidated financial results for the period ended December 31, 2021
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
Subscribe To Our Newsletter & Stay Updated
